Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy

B. Douglas Smith, Dalia Mahmoud, Stacey Dacosta-Byfield, Virginia M. Rosen

Research output: Contribution to journalArticlepeer-review

Abstract

This study utilized claims data from a national US commercial health insurer to examine rates of cytopenia-related complications (significant bleeding, infection) and health care utilization (emergency room visits, inpatient hospitalizations) among patients with myelodysplastic syndromes (MDS) within predefined periods of transfusion activity and active therapy. Periods with no transfusions, regardless of relationship to treatment intervention, were associated with lower rates of cytopenia-related complications. These data suggest that eliminating or reducing the need for transfusions may help to reduce MDS-related medical problems, and treatment toward that goal should be considered in patients with MDS needing transfusions.

Original languageEnglish (US)
Pages (from-to)1119-1125
Number of pages7
JournalLeukemia and Lymphoma
Volume55
Issue number5
DOIs
StatePublished - May 2014
Externally publishedYes

Keywords

  • Cytopenia
  • MDS
  • Myelodysplastic syndromes
  • Outcomes
  • Transfusion
  • Utilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy'. Together they form a unique fingerprint.

Cite this